Search
EHT899
go.drugbank.com/drugs/DB05108ExperimentalEHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Temanogrel
go.drugbank.com/drugs/DB05227InvestigationalAPD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.
XL765
go.drugbank.com/drugs/DB05241InvestigationalXL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.
Ostabolin-C
go.drugbank.com/drugs/DB05536InvestigationalOstabolin C was under investigation in clinical trial NCT00787358 (A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT
Synonyms: -GLUTAMYL-L-ISOLEUCYL-L-GLUTAMINYL-L-LEUCYL-L-METHIONYL-L-HISTIDYL-L-ASPARAGINYL-L-LEUCYLGLYCYL-L-LYSYL-L-HISTIDYL-L-LEUCYL-L-ASPARAGINYL-L-SERYL-L-METHIONYL-L-.ALPHA., L-VALINAMIDE, L-SERYL-L-VALYL-L-SERYL-L-.ALPHA.AVI-4065
go.drugbank.com/drugs/DB05620InvestigationalAVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc.
ISIS 14803
go.drugbank.com/drugs/DB05803InvestigationalISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits
Apatorsen
go.drugbank.com/drugs/DB06094InvestigationalApatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human cancers